Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy

Multiple Sclerosis Journal

Volumn 19, Issue 9, 2013, Pages 1209-1212

  Harrer, A ^a   Tumani, H ^b   Niendorf, S ^b   Lauda, F ^b   Geis, C ^c   Weishaupt, A ^c   Kleinschnitz, C ^c   Rauer, S ^d   Kuhle, J ^e   Stangel, M ^f   Weber, F ^g   Uhr, M ^g   Linnebank, M ^h   Wildemann, B ⁱ   Jarius, S ⁱ   Guger, M ^j   Ayzenberg, I ^k   Chan, A ^k   Zettl, U ^l   Wiendl, H ^m   Pilz, G ^a   Hitzl, W ^a   Weber, J R ⁿ   Kraus, J ^a   more..

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF BASEL   (Switzerland)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j KEPLER UNIVERSITY HOSPITAL   (Austria)

^k ST JOSEF HOSPITAL   (Germany)

^l UNIVERSITY OF ROSTOCK   (Germany)

^m UNIVERSITY OF MÜNSTER   (Germany)

ⁿ Klinikum Klagenfurt   (Austria)

more..

Author keywords

cerebrospinal fluid; intrathecal IgG; multiple sclerosis; Natalizumab; oligoclonal bands

Indexed keywords

IMMUNOGLOBULIN G; NATALIZUMAB; OLIGOCLONAL BAND;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BLOOD CEREBROSPINAL FLUID BARRIER; CELL ACTIVITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; SAMPLE SIZE;

CEREBROSPINAL FLUID; INTRATHECAL IGG; MULTIPLE SCLEROSIS; NATALIZUMAB; OLIGOCLONAL BANDS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84881078675     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512463483     Document Type: Article

References (10)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
2. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006 ; 59: 743-747
3. von Glehn F, Farias AS, de Oliveira AC, et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler. 2012 ; 18: 1038-1041
4. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures. J Neurol Sci. 2011 ; 306: 82-90
5. Petereit HF, Reske D. Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implications. Cerebrospinal Fluid Res. 2005 ; 2: 3
6. Reiber H. Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998 ; 4: 99-107
7. Reiber H. Flow rate of cerebrospinal fluid (CSF) - a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994 ; 122: 189-203
8. Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology. 2011 ; 76: 1214-1221
9. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010 ; 67: 707-714
10. von Budingen HC, Bar-Or A, Zamvil SS. B cells in multiple sclerosis: Connecting the dots. Curr Opin Immunol. 2011 ; 23: 713-720